The nodal status of patients at diagnosis was as follows: 525 patients (44%) were node negative before neoadjuvant treatment (n = 235 luminal BC (45%); n = 171 TNBC (45.5%); n = 119 HER-2 positive BC (40.3%)). Here, ERBB2 is linked to breast cancer.